January 3, 2018 / 1:22 PM / 6 months ago

BRIEF-Landmark Schizophrenia Data Receive FDA Approval For Inclusion In Invega Sustenna (Paliperidone Palmitate) Label

Jan 3 (Reuters) - Johnson & Johnson:

* LANDMARK SCHIZOPHRENIA DATA THAT BRING HOPE IN BREAKING THE CYCLE OF HOSPITALIZATION AND INCARCERATION RECEIVE FDA APPROVAL FOR INCLUSION IN INVEGA SUSTENNA® (PALIPERIDONE PALMITATE) LABEL

* JANSSEN PHARMACEUTICALS SAYS INVEGA SUSTENNA IS THE FIRST ANTIPSYCHOTIC TO HAVE U.S. FDA APPROVE INCLUSION OF REAL-WORLD DATA IN ITS PRODUCT LABELING Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below